- Home
- EHC vs HOLX Comparison
EHC vs HOLX Comparison
Compare EHC & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EHC | HOLX |
|---|---|---|
| Founded | 1983 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medical Electronics |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 16.6B |
| IPO Year | 1986 | 1990 |
Fundamental Metrics
Financial Performance| Metric | EHC | HOLX |
|---|---|---|
| Price | $112.45 | $74.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 15 |
| Target Price | ★ $141.88 | $79.64 |
| AVG Volume (30 Days) | 657.7K | ★ 3.0M |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | ★ 27.89 | N/A |
| EPS | ★ 5.29 | 2.49 |
| Revenue | ★ $5,795,600,000.00 | $4,100,500,000.00 |
| Revenue This Year | $11.54 | $6.69 |
| Revenue Next Year | $8.78 | $5.74 |
| P/E Ratio | ★ $21.21 | $30.11 |
| Revenue Growth | ★ 11.13 | 1.74 |
| 52 Week Low | $87.85 | $51.90 |
| 52 Week High | $127.99 | $80.31 |
Technical Indicators
Market Signals| Indicator | EHC | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 67.93 |
| Support Level | $111.96 | $74.55 |
| Resistance Level | $117.50 | $75.12 |
| Average True Range (ATR) | 2.14 | 0.28 |
| MACD | 0.18 | -0.14 |
| Stochastic Oscillator | 26.60 | 78.92 |
Price Performance
Historical ComparisonAbout EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About HOLX Hologic Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.